Latest Breaking News On - Additional phase - Page 1 : vimarsana.com

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesJoyce allaireSheryl seapyDavid boyerDrug administrationAnnexon incLifesci advisorsAssociation for researchSecurities exchangeEuropean medicines agencyVitreous associates medical groupVision associated structuresGeographic atrophyGlobal pivotal phaseControl expectedPivotal phase

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesSheryl seapyJoyce allaireDavid boyerDrug administrationAnnexon incLifesci advisorsSecurities exchangeAssociation for researchVitreous associates medical groupEuropean medicines agencyGlobal pivotal phaseControl expectedPivotal phaseExpected second halfPriority medicine

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q.

United statesCity ofUnited kingdomMark dransfieldChristine foxLee rothMereo biopharmaDenise scots knightUltragenyx pharmaceutical incTranslational sciencesDivision of pulmonologyMereo biopharma groupIndustry programExchange commissionNational centerUnited states securities exchange

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChris taylorDan budwickBrian goffExchange commissionAgios pharmaceuticals incAmerican society of hematologyAgios pharmaceuticalsBusiness developmentCorporate communicationsCompany expects four additional phaseFranchise has demonstrated clinical efficacyFour hematological diseasesIncluding new positive phaseNon transfusion dependent thalassemia

Lyra Therapeutics: A Risk Assessment (NASDAQ:LYRA)

Lyra Therapeutics: A Risk Assessment (NASDAQ:LYRA)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Bob langerLyra therapeuticsAdditional phase